The option of compassionate use in metastatic melanoma - Way out of a therapeutic dilemma?

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 8, 2009, Pages 671-678

  Tsianakas, Athanasios ^a   Schiller, Meinhard ^a   Luger, Thomas A ^a   Sunderkötter, Cord ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Chemotherapy; Compassionate use; Metastasized melanoma

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; OBLIMERSEN; PROTEIN BCL 2;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPASSIONATE USE; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OFF LABEL DRUG USE; REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 68549101719     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07028.x     Document Type: Review

References (14)

1. Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv 1994 19-20 : 219 240.
2. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001 14 : 280 290.
3. Eggermont AM, Kirkwood JM. Reevaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004 40 : 1825 1836.
4. Nashan D, Müller ML, Grabbe S, Wustlich S, Enk A. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. J Eur Acad Dermatol Venereol 2007 21 : 1305 1318.
5. Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol) 2001 13 : 458 465.
6. Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Bröcker EB, Neumann C, Rünger TM, Schuler G, von den Driesch P, Müller I, Paul E, Patzelt T, Reitz M. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002 86 : 179 184.
7. Dorval T, Négrier S, Chevreau C, Avril MF, Baume D, Cupissol D, Oskam R, de Peuter R, Vinke J, Herrera A, Escudier B. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 1999 85 : 1060 1066.
8. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003 4 : 748 759.
9. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002 20 : 2045 2052.
10. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res 2008 18 : 152 160.
11. EMEA (European Medicinal Agency) Guideline on Compassionate Use of Medicinal Products : http://www.emea.europa.eu/pdfs/human/euleg/2717006enfin.pdf
12. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Müller M, Wolff K, Eichler HG, Pehamberger H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998 4 : 232 234.
13. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002 12 : 193 213.
14. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006 24 : 4738 4745.